Kentucky Cancer Registry Spring Training 2017
|
|
|
- Bertina Newman
- 5 years ago
- Views:
Transcription
1 Kentucky Cancer Registry Spring Training 2017
2 What we will cover Coding instructions for grade Case examples addressing some areas of confusion for grade New grade data items coming in 2018 TNM
3 Where to find Grade coding instructions? /grade/grade-2014-codinginstructions.pdf
4 Grade instructions 1-2 Read you instructions and keep them handy at all times. 1. Systemic treatment and radiation can alter a tumor s grade. Therefore, it is important to code grade based on information prior to neoadjuvant therapy even if grade is unknown. 2. Code the grade from the primary tumor only. Do NOT code grade based on metastatic tumor or recurrence. In the rare instance that tumor tissue extends contiguously to an adjacent site and tissue from the primary site is not available, code grade from the contiguous site. If primary site is unknown, code grade to 9.
5 Grade instruction 3 3. Code the grade shown below (6th digit) for specific histologic terms that imply a grade. Carcinoma, undifferentiated (8020/34) Carcinoma, anaplastic (8021/34) Follicular adenocarcinoma, well differentiated (8331/31) Thymic carcinoma, well differentiated (8585/31) Sertoli-Leydig cell tumor, poorly differentiated (8631/33) Sertoli-Leydig cell tumor, poorly differentiated with heterologous elements (8634/33) Undifferentiated sarcoma (8805/34) Liposarcoma, well differentiated (8851/31) Seminoma, anaplastic (9062/34) Malignant teratoma, undifferentiated (9082/34) Malignant teratoma, intermediate type (9083/32) Intraosseous osteosarcoma, well differentiated (9187/31) Astrocytoma, anaplastic (9401/34) Oligodendroglioma, anaplastic (9451/34) Retinoblastoma, differentiated (9511/31) Retinoblastoma, undifferentiated (9512/34)
6 Grade instruction 4a-4b 4a. Make sure to code the grade of the malignancy Do not code dysplasia grade Example high grade dysplasia (CIN III) Code the grade for an in situ tumor if the grade is given 4b. If there are both in situ and invasive components, code only the grade for the invasive portion even if its grade is unknown.
7 Grade instruction 5 5. If there is more than one grade, code the highest grade within the applicable system. Code the highest grade even if it is only a focus. Code grade in the following priority order using the first applicable system: Special grade systems for the sites listed in Coding for Solid Tumors #6 Differentiation: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system Nuclear grade: use Coding for Solid Tumors #7: 2-, 3-, or 4- grade system If it isn t clear whether it is a differentiation or nuclear grade and a 2-, 3-, or 4- grade system was used, code the specific grade. Terminology (use Coding for Solid Tumors #8)
8 Grade instruction 6 6. Use the information from the special grade systems first. If no special grade can be coded, continue with Coding for Solid Tumors #7-9. Special grade systems for solid tumors CS Schema Breast Prostate Special Grade System Nottingham or Bloom-Richardson (BR) Score/Grade (SSF7) Gleason's Score on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) (SSF 8) Prostate Gleason's Score on Prostatectomy/Autopsy (SSF 10) Heart, Mediastinum Grade for Sarcomas (SSF 1) Peritoneum Grade for Sarcomas (SSF 1) Retroperitoneum Grade for Sarcomas (SSF 1) Soft Tissue Grade for Sarcomas (SSF 1) Kidney Parenchyma Fuhrman Nuclear Grade (SSF 6)
9 Grade instruction 7 7. Use the Two-, Three- or Four-grade system information If you have any confusion on what grading system is being used you should refer to the pathologist directly or cancer committee or cancer conferences to ask the pathologist to confirm/verify. Two-grade system Term Description Grade Code 1/2, I/II Low grade 2 1 2/2, II/II High grade 4 3 Exception for Breast and Prostate Grade Code In transitional cell carcinoma for bladder, the terminology high grade TCC and low grade TCC are coded in the two-grade system.
10 Grade instruction 7 continued 7. Use the Two-, Three- or Four-grade system information Three-grade system Term Description Grade Code 1/3 Low grade 2 1 2/3 Intermediate grade 3 2 3/3 High grade 4 3 Exception for Breast and Prostate Grade Code
11 Grade instruction 7 continued 7. Use the Two-, Three- or Four-grade system information Four-grade system Term Description Grade Code 1/4 Grade I; Well differentiated 1 2/4 Grade II; Moderately differentiated 2 3/4 Grade III; Poorly differentiated 3 4/4 Grade IV; Undifferentiated 4
12 Grade instruction 8 8. Terminology: use the Description column or the Grade column to code grade. Breast & Prostate use the same grade code with a few noted exceptions. Description Grade Assigned Grade Code Exception for Breast and Prostate Grade Code Differentiated, NOS I 1 Well differentiated I 1 Only stated as Grade I I 1 Fairly well differentiated II 2 Intermediate differentiation II 2 Low grade I-II 2 1 Mid differentiated II 2 Moderately differentiated II 2 Moderately well differentiated II 2 Partially differentiated II 2 Partially well differentiated I-II 2 1 Relatively or generally well differentiated II 2 Only stated as Grade II II 2
13 Grade instruction 8 continued Description Grade Assigned Grade Code Exception for Breast and Prostate Grade Code Medium grade, intermediate grade II-III 3 2 Moderately poorly differentiated III 3 Moderately undifferentiated III 3 Poorly differentiated III 3 Relatively poorly differentiated III 3 Relatively undifferentiated III 3 Slightly differentiated III 3 Dedifferentiated III 3 Only stated as Grade III III 3 High grade III-IV 4 3 Undifferentiated, anaplastic, not differentiated IV 4 Only stated as Grade IV IV 4 Non-high grade 9
14 Grade instruction 9 9. If no description fits or grade is unknown prior to neoadjuvant therapy, code as a 9 (unknown).
15 Grade Examples Example 1 Example 2 Example 3 Example 4 Example 5 Example 6
16 New Grade Data Items in 2018 AJCC Grade Clinical To be used when assigning AJCC clinical stage AJCC Grade Pathologic To be used when assigning AJCC Pathologic stage
17 TNM Staging The most important thing to remember is to open your manuals for each case Is the histology included in the chapter? Are the criteria for staging being met? Clinical staging requires that the cancer was known or suspected Pathologic must meet the resection criteria
18 Questions?
Instructions for Coding Grade for 2014+
Instructions for Coding for 2014+ GRADE, DIFFERENTIATION OR CELL INDICATOR Item Length: 1 NAACCR Item #: 440 NAACCR Name:, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for
Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
WHAT S NEW: JANUARY-FEBRUARY 14 FROM THE COC-SEER-NPCR TECHNICAL WORKING GROUP
JANUARY-FEBRUARY 14 WHAT S NEW: The following information is currently available on the FCDS website. FROM THE COC-SEER-NPCR TECHNICAL WORKING GROUP FLORIDA ANNUAL CANCER REPORT: INCIDENCE AND MORTALITY
2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+
2014 Grade Coding Instructions ICD-O-3 Updates 1 I M P L E M E N T A T I O N T I M E L I N E ( S ) 2 0 1 4 F C D S D A M A P P E N D I X H A N D O U T S F C D S A N N U A L C O N F E R E N C E O R L A
2018 New Grade Coding Rules It s a Good Thing!
2018 New Grade Coding Rules It s a Good Thing! Presented by Donna M. Hansen, CTR California Cancer Registry NAACCR Webinar May 1, 2018 & May 2, 2018 1 Acknowledgement Special Thanks To: Jennifer Ruhl,
MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
CODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
Collaborative Staging
Slide 1 Collaborative Staging Site-Specific Instructions Prostate 1 In this presentation, we are going to take a closer look at the collaborative staging data items for the prostate primary site. Because
Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
Outline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.
1 How to Use the AJCC Cancer Staging Manual, 7 th ed. FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015 Steven Peace, CTR Outline 2 History, Purpose and Background Purchase and Ordering Information
Interactive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
ICD-O CODING Third Edition
Slide 1 ICD-O CODING Third Edition PART II The ICD-O-3 Coding Rules for Topography and Morphology This is part 2 of a 2-part presentation. Use the navigation buttons below this panel to advance the slides.
Genitourinary. Presentation Outline. Genitourinary System 12/14/2011. FCDS 2011 Educational Webcast Series December 15, 2011
Genitourinary FCDS 2011 Educational Webcast Series December 15, 2011 1 Susan Smith Pierce, CTR Gema Midence, MBA, CTR Steven Peace, BS, CTR Presentation Outline Overview including Anatomy and General Information
CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.
CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version 02.03.02 (Effective date: 1/1/2011) Outline of Presentation Purpose AJCC TNM Classification Eval data
Quiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
Colon and Rectum: 2018 Solid Tumor Rules
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent
A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR
A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR Survey Questions and Answers 250 Responses 2 Question #1 A gentleman
NAACCR Webinar Series 1
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar
NAACCR Grade 2018 Q & A
NAACCR Grade 2018 Q & A GRADE RULES Q: Can you assign a pathologic grade if bx of highest T AND bx of highest N, where case meets criteria for pathologic staging? A:The grade rules indicate for a pathological
FINALIZED SEER SINQ QUESTIONS April July, 2017
20170040 Source 1: 2016 SEER Manual pgs: 91 Source 2: 2007 MP/H Rules Notes: Lung MP/H Rules/Histology--Lung: What is the histology code for lung cancer case identified pathologically from a metastatic
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification
Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification A1: Yes. See below. I don't think it will have a start date. Clarification
Collecting Cancer Data: Breast. Prizes! Collecting Cancer Data: Breast 8/4/ NAACCR Webinar Series 1. NAACCR Webinar Series
Collecting Cancer Data: Breast NAACCR 2008 2009 Webinar Series Prizes! Question of the Month! The participant that submits the best question of the session will receive a fbl fabulous Pi Prize! Shannon
COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING
COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING COLON AND RECTUM SOLID TUMOR RULES Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent Terms Terms that are NOT Equivalent
2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018?
2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018? SESSION 2 10/20/17 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session, the Q&A,
Kidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
Prostate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013
Tumor Comparison NAACCR Death Clearance Manual Update Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013 Tumor Comparison The process of comparing the registry s tumors to the
Introduction & Descriptors
AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.
Slide 1 2007 New Data Items Data Due in: Days In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules. Slide 2 5 New Data Items Ambiguous Terminology
AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by
AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by
AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Presentation Outline Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 General Information
Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04
Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04 X:\FCDS_PUB\wwwroot\downloads\Teleconfere nces\2013 FCDS Educational Webcast Series February 28, 2013 1 Steven Peace, BS, CTR Susan Smith
CASEFINDING. KCR Abstractor s Training
CASEFINDING KCR Abstractor s Training 1 Introduction Casefinding Definition Purpose Methods Sources vs Resources Reportable Cancer Conditions Non-Reportable Conditions Ambiguous Terminology 2 https://www.google.com/search?q=puzzle+pieces&client=firefox-a&hs=mdc&rls=org.mozilla
Introduction to ICD-O-3 coding rules
Introduction to ICD-O-3 coding rules Weena Laddachayaporn, MD National Cancer Institute, Bangkok, Thailand ICD-O-3 The International Classification of Diseases for Oncology Is a coding system for primary
Change Log V1.3- v1.4
Change Log V1.3- v1.4 This document shows the changes that were made to the SSDI manual and the Grade manual for the SEER*RSA version 1.4 release on (Date TBD). SSDI Manual Section: General Instructions
Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I SUMMARY OF YEAR 2004 DATA CHANGES This document will provide a summary
The European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?
AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM? FCRA Annual Conference Boca Raton, Florida 7/26/2016 Steven Peace, CTR 1 Introduction Order AJCC Cancer Staging Manual, 7 th ed. How To Use - AJCC Cancer
Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
FINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
SEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
SEER Appendix C: Site Specific Coding Guidelines
SEER Appendix C: Site Specific Coding Guidelines BLADDER C670 C679 Primary Site C670 Trigone of bladder Base of bladder Floor Below interureteric ridge (interureteric crest, or interureteric fold) C671
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care
Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.
Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
5/8/2014. AJCC Stage Introduction and General Rules. Acknowledgements* Introduction. Melissa Pearson, CTR North Carolina Central Cancer Registry
AJCC Stage Introduction and General Rules Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
Vivien W. Chen, PhD Mei-Chin Hsieh, MSPH, CTR Lisa A. Pareti, BS, CTR Xiao-Cheng Wu, MD, MPH, CTR. NAACCR Conference Portland, Oregon, June 5-7, 2012
Vivien W. Chen, PhD Mei-Chin Hsieh, MSPH, CTR Lisa A. Pareti, BS, CTR Xiao-Cheng Wu, MD, MPH, CTR NAACCR Conference Portland, Oregon, June 5-7, 2012 Background Purpose/Objective Methods Results Implications/Next
NAACCR Webinar 2018 SeriesImplementations and Timelines
NAACCR 2015-2016 Webinar 2018 SeriesImplementations and Timelines August 8, 2017 Session 1 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session,
Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
2018 Updates to National Standards
2018 Updates to National Standards 1 F C D S A N N U A L C O N F E R E N C E O R L A N D O, F L O R I D A 7 / 2 6 / 2 0 1 7 S T E V E N P E A C E, C T R ICD-O-3 New Histology Codes ICD-O-3 Behavior Changes
Pathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
FORDS. Facility Oncology Registry Data Standards Revised for 2010 (Incorporates all updates since originally published in July 2002)
FORDS Facility Oncology Registry Data Standards Revised for 2010 (Incorporates all updates since originally published in July 2002) Includes updates to May 1, 2010 See Appendix C for a summary of changes.
What s New for 8 th Edition
What s New for 8 th Edition KCR 2018 SPRING TRAINING Overview What s New New Chapters for 8 th Editions Chapters That Split in 8 th Edition Merged 8 th Edition Chapters Blanks vs Xs How to Navigate Through
NPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
NEW JERSEY STATE CANCER REGISTRY
NEW JERSEY STATE CANCER REGISTRY SEER Summary Stage 2000/SEER Summary Stage 2018 Comparison Guide Updated 5-16-18 SEER Summary Stage 2000/SEER Summary Stage 2018 Comparison Developed by the New Jersey
Cerebral Parenchymal Lesions: I. Metastatic Neoplasms
Chapter 4 Cerebral Parenchymal Lesions: I. Metastatic Neoplasms After one has reasonably ruled out the possibility of a nonneoplastic diagnosis (see Chap. 3), one is left with considering a diagnosis of
Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1
MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the
Boot Camp Case Scenarios
Boot Camp Case Scenarios Case Scenario 1 Patient is a 69-year-old white female. She presents with dyspnea on exertion, cough, and right rib pain. Patient is a smoker. 9/21/12 CT Chest FINDINGS: There is
Testicular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors
Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors Presented to NAACCR Annual Conference 2012 Serban Negoita, MD, DrPH; Marsha Dunn,
Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
![Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]](/thumbs/82/86783199.jpg "Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]")
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
2010 Update. NAACCR Webinar Series 1 4/1/2010. Agenda. Access to 2010 Information. CSv2. Collecting Cancer Data: Soft Tissue Sarcoma
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Soft Tissue Sarcoma, Neuroendocrine Tumors (NET) and Gastrointestinal Stromal Tumors (GIST) Agenda Updates Soft Tissue Sarcoma Overview CSv2 MP/H
Shore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009
Collecting Cancer Data: Prostate NAACCR 2008-2009 Webinar Series June 11, 2009 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview 2008-2009 NAACCR Webinar Series
VISUAL EDITING GUIDELINES March 2015 (revised June 2015)
March 2015 (revised June 2015) Developed for The Cancer Registry of Greater California under the direction of Winny Roshala, BA, CTR, Data Quality Control Director By the following contributing Authors:
2018 Summary Stage PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Summary Stage PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgement Jennifer Ruhl, NCI SEER 3 Introduction 2018 SUMMARY STAGE 2018 Summary Stage 4 First update since 2001
Case Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
Interactive Discussion of Part I CS Coding Instructions: Working the Cases
Interactive Discussion of Part I CS Coding Instructions: Working the Cases April Fritz, RHIT, CTR Donna M. Gress, RHIT, CTR Jennifer Ruhl, RHIT, CCS, CTR This presentation was supported by the Cooperative
Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,
Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, 2004-2012 Jeanne Whitlock, MSLS, CTR Julie George, MS Ron Shore, MPH Fawn D. Vigneau, JD, MPH Metropolitan
Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture
Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.
NPCR s TNM Stage Calculator
NPCR s TNM Stage Calculator A Tool for Central Registry Quality Control and Consolidation Assistance NAACCR Annual Meeting June 16, 2016 Jennifer Seiffert Northrop Grumman Under contract to NPCR Joseph
ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III.
ONCOLOGY Csaba Bödör Department of Pathology and Experimental Cancer Research 2018. november 19., ÁOK, III. bodor.csaba1@med.semmelweis-univ.hu ONCOLOGY Characteristics of Benign and Malignant Neoplasms
Urology An introduction to cut up DR J R GOEPEL
Urology An introduction to cut up DR J R GOEPEL Overview Principles Individual organs Small pieces Partial resections Whole organs Data recording and data sets Principles You are working for the patient
Prostate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
Evaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R
Evaluation of Abstracting: Cancers Diagnosed in 2001 MCSS Quality Control Report 2005:2 Elaine N. Collins, M.A., R.H.I.A., C.T.R Jane E. Braun, M.S., C.T.R John Soler, M.P.H September 2005 Minnesota Department
Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1
Coding Pitfalls 2010 2011 September 1, 2011 NAACCR 2010 2011 Webinar Series Questions Please submit questions about today s presentation through the Q&A (?) panel Fabulous Prizes!!! For the best question
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
Staging for Residents, Nurses, and Multidisciplinary Health Care Team
Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage
Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.
Q&A Breast Webinar Q: One of my investigators is interested in knowing when Oncotype DX data collection was implemented. That data is collected in SSFs 22 and 23. I remember that the SSFs for breast were
Coding Pitfalls 9/11/14
Coding Pitfalls 2013 2014 NAACCR Webinar Series September 11, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =
Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This
Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012
Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q: Will sticky notes be transferrable from the previous electronic version of CS to the updated version? A: It is our
3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours
60 3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours Compilation and editing and of this volume: Prof. Chandu de Silva (Consultant Histopathologist) List of contributors Consultant
WHAT S NEW: MAY/JUNE REGISTRATION ONLINE: register.pl
Monthly Journal of Updates and Information MAY/JUNE 2012 WHAT S NEW: The following information is currently available on the FCDS website. The 2012 Florida Cancer Data System Annual Conference is being